The European Bispecific & Multispecific Antibody Congress Returns February 2024

Achieving Successful Clinical Translation Through Refinement of Design & Engineering, Expansion of Target Classes and Novel Biology, and Demonstration of Technologies in the Clinic

REGISTER YOUR INTEREST
Amsterdam, Netherlands
February 2024

Click here to find out about the all the networking opportunities and the full list of sessions from 2023 including presentations from Innate Pharma, Merck, Roche and Novartis.

Talk to our team today to discuss your marketing objectives.

How To Get Involved

PARTNER WITH US

It's never too early to get involved! Based on your objectives, we can create bespoke packages designed specifically for you.

From presenting your expertize on the main stage to hosting the infamous Drinks Reception. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

Discuss your objectives with Jack Tollervey, Commercial Partnerships Manager; [email protected]

GET IN TOUCH HERE

REGISTER AS A DELEGATE

Step into interactive discussions and engaging presentations on the key challenges and opportunities presented.

Register your interest and be the first to hear updates on the 2024 Congress.

REGISTER YOUR INTEREST HERE

Why Attend

The field of multi-specifics has accelerated, and substantial interest is owed to its flexibility, modularity, specificity and promise to be the ultimate set of modalities for precision oncology and beyond. As the field patiently waits for clinical trial readouts to feed into and optimise the overwhelming amount of preclinical candidates in the space, some say we are entering the next era and well into the 4th wave of drug discovery, beyond current targets and disease indications. Ongoing research efforts in academia and industry prepare us for the next wave of challenges that need to be overcome:

  • Exploring novel biology, target and pathway selection for current and novel formats geared towards optimizing cancer targets and novel indications
  • Innovative design and engineering challenges, developing assays that explore innovative format architecture in a rational way, away from long bouts of archaic trial and error and well into modelling and prediction
  • Improving safety and efficacy profiles of current and emerging candidates
  • Improving immune response modulation: to support the performance of multispecific drugs, exploring ways to tune/steer the immune response or induce synthetic immunity to mimic endogenous immune response, and study and prevent resistance mechanisms

AUDIENCE BREAKDOWN

14%
Academics
42%
Biotechs
28%
Pharma
16%
Solution/Technology Providers

Academics

Biotechs

Pharma

Solution/Technology Providers

2023 Speakers

 

Wei Xu

Chief Scientific Officer
Numab Therapeutics

Wei Xu

Chief Scientific Officer
Numab Therapeutics

Wei Xu

Chief Scientific Officer
Numab Therapeutics
 

Alexander Schinagl

Chief Technology Officer
OncoOne

Alexander Schinagl

Chief Technology Officer
OncoOne

Alexander Schinagl

Chief Technology Officer
OncoOne
 

Colette Johnston

VP, Discovery
Crescendo Biologics

Colette Johnston

VP, Discovery
Crescendo Biologics

Colette Johnston

VP, Discovery
Crescendo Biologics
 

Jonathan Davis

VP, Innovation & Strategy
Invenra

Jonathan Davis

VP, Innovation & Strategy
Invenra

Jonathan Davis

VP, Innovation & Strategy
Invenra
 

Laura Von Schantz

Vice President, Discovery
Alligator Bioscience

Laura Von Schantz

Vice President, Discovery
Alligator Bioscience

Laura Von Schantz

Vice President, Discovery
Alligator Bioscience
 

Anne Goubier

Vice President, Immuno Biology
Molecular Partners

Anne Goubier

Vice President, Immuno Biology
Molecular Partners

Anne Goubier

Vice President, Immuno Biology
Molecular Partners
 

Stefan Zielonka

Director
Merck KGaA

Stefan Zielonka

Director
Merck KGaA

Stefan Zielonka

Director
Merck KGaA
 

Anders Carlsson

CEO
Bionamic

Anders Carlsson

CEO
Bionamic

Anders Carlsson

CEO
Bionamic
 

Peter Lowe

Director, Antibody Engineering
Merus

Peter Lowe

Director, Antibody Engineering
Merus

Peter Lowe

Director, Antibody Engineering
Merus
 

Simone de Haij

Director, Functional Characterization & Bioassays Lead
Genmab

Simone de Haij

Director, Functional Characterization & Bioassays Lead
Genmab

Simone de Haij

Director, Functional Characterization & Bioassays Lead
Genmab
 

Pauline Van Helden

Director, Translational Research
LAVA Therapeutics

Pauline Van Helden

Director, Translational Research
LAVA Therapeutics

Pauline Van Helden

Director, Translational Research
LAVA Therapeutics
 

Stephen Harper

Associate Director, Protein Engineering Research
Immunocore

Stephen Harper

Associate Director, Protein Engineering Research
Immunocore

Stephen Harper

Associate Director, Protein Engineering Research
Immunocore
 

Qian Zhang

Global Head of Lead Evalution and Protein Science
HiFiBio Therapeutics

Qian Zhang

Global Head of Lead Evalution and Protein Science
HiFiBio Therapeutics

Qian Zhang

Global Head of Lead Evalution and Protein Science
HiFiBio Therapeutics
 

Claudio Sustmann

Senior Leader, Antibody Discovery & External Innovation, Large Molecules Research
Roche

Claudio Sustmann

Senior Leader, Antibody Discovery & External Innovation, Large Molecules Research
Roche

Claudio Sustmann

Senior Leader, Antibody Discovery & External Innovation, Large Molecules Research
Roche
 

Roberto De Luca

Head of Therapeutic Antibodies
Philogen

Roberto De Luca

Head of Therapeutic Antibodies
Philogen

Roberto De Luca

Head of Therapeutic Antibodies
Philogen
 

David Eisen

Head of Analytical Development
Pieris Pharmaceuticals

David Eisen

Head of Analytical Development
Pieris Pharmaceuticals

David Eisen

Head of Analytical Development
Pieris Pharmaceuticals
 

Regis Cebe

Principal Scientist II
Novartis

Regis Cebe

Principal Scientist II
Novartis

Regis Cebe

Principal Scientist II
Novartis
 

Jeanette Leusen

Head of the Immunotherapy Group and UMAB
UMCU

Jeanette Leusen

Head of the Immunotherapy Group and UMAB
UMCU

Jeanette Leusen

Head of the Immunotherapy Group and UMAB
UMCU
 

Harold Kolmar

Professor and Head, Institute for Organic Chemistry and Biochemistry
Technische Universität Darmstadt

Harold Kolmar

Professor and Head, Institute for Organic Chemistry and Biochemistry
Technische Universität Darmstadt

Harold Kolmar

Professor and Head, Institute for Organic Chemistry and Biochemistry
Technische Universität Darmstadt
 

Mark Chiu

President & CEO
Tavotek Therapeutics

Mark Chiu

President & CEO
Tavotek Therapeutics

Mark Chiu

President & CEO
Tavotek Therapeutics
 

Stuart Barnscher

Director, Preclinical Programs, ADC Research
Zymeworks

Stuart Barnscher

Director, Preclinical Programs, ADC Research
Zymeworks

Stuart Barnscher

Director, Preclinical Programs, ADC Research
Zymeworks
 

Marie-Cecile van de Lavoir, DVM, PhD

Sr. Vice President, Technical Operations and Genetics
OmniAb

Marie-Cecile van de Lavoir, DVM, PhD

Sr. Vice President, Technical Operations and Genetics
OmniAb

Marie-Cecile van de Lavoir, DVM, PhD

Sr. Vice President, Technical Operations and Genetics
OmniAb

The Agenda

The European Bispecific & Multispecific Antibody Congress 2023 agenda is here! Simply fill out the short form and access your copy immediately. 

Key content covers:

  1. Improving the efficacy and quality of bispecific antibodies through exploration of the best design 
  2. Optimising and future proofing the multispecifics landscape by analysing format and design trends within the clinic
  3. Analysing trends in format and design that have shown success in the clinic and how to inform and optimise future candidates
  4. De-risking multispecific development pipelines through the integration of analytics in early format design and engineering
  5. Implementing more innovative strategies for developing multispecific NK cell engagers

DOWNLOAD THE 2023 AGENDA

2023 Partners

Platinum Partners

Silver Partner

Event Partner

Become a partner

Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.

Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.

Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.

Find out more by calling us at +44 (0)20 3696 2920 or email Jack Tollervey at [email protected] 

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us